Ophthalmology Doctors in Beverly, MA Accepting Medicare

5 Ophthalmology doctors found. Showing 1 - 5

Dr. David S Hutchison, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 77 Herrick Street, Suite 102 Ophthalmic Consultants Of Boston, Beverly, MA 01915 Phone: 978-922-7303    Fax: 978-927-4969

Danielle M Ledoux, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 77 Herrick St Ste 102, Beverly, MA 01915 Phone: 978-338-4321    Fax: 978-927-1010

William Gregory Stinson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 75 Herrick St, Suite 215, Beverly, MA 01915 Phone: 978-922-1390

Dr. Shahrokh Charles Khani, MD PHD Ophthalmology - Retina Specialist Medicare: Accepting Medicare Assignments Practice Location: 900 Cummings Center, Suite 303v, Beverly, MA 01915 Phone: 978-922-1344    Fax: 978-922-1346

Poonam N. Doshi, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 77 Herrick St Ste 102, Beverly, MA 01915 Phone: 978-338-4321

News Archive

Novel consortium aims to create new paradigm of cancer drug discovery

Scientists from two U.S. national laboratories, industry and academia today launched an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies.

Anti-LG3 associated with high rate of organ rejection during transplantation

​A team led by Dr. Marie-Jos-e H-bert from the University of Montreal Hospital* Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies - anti-LG3 - which when activated lead to severe rejection episodes associated with a high rate of organ loss.

Cequent Pharmaceuticals' IND application for CEQ508 approved for clinical trial

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday.

Bribery in the healthcare does not pay off

Bribery in the public healthcare does not solve the problem of poor quality of services, and even exacerbates it, researchers argue.

Health providers embrace the potential of ACOs

News outlets report on some health care providers' views of the potential of accountable care organizations to improve quality and reduce costs.

Read more Medical News

› Verified 8 days ago